Antitumour effects of temozolomide in a man with a large, invasive prolactin‐producing pituitary neoplasm
2006; Wiley; Volume: 65; Issue: 4 Linguagem: Inglês
10.1111/j.1365-2265.2006.02653.x
ISSN1365-2265
AutoresLuis V. Syro, Humberto Uribe, Luis C. Penagos, León Darío Ortiz, Camilo E. Fadul, Éva Horváth, Kálmán Kovács,
Tópico(s)Neuroblastoma Research and Treatments
ResumoClinical EndocrinologyVolume 65, Issue 4 p. 552-553 Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm Luis V. Syro, Luis V. Syro Department of Neurosurgery, Hospital Pablo Tobon Uribe and Clinica Medellin, Medellin, Colombia,Search for more papers by this authorHumberto Uribe, Humberto Uribe Department of Neurosurgery, Clinica SOMA, Medellin, Colombia,Search for more papers by this authorLuis C. Penagos, Luis C. Penagos Division of Otolaryngology, Clinica Medellin, Medellin, Colombia,Search for more papers by this authorLeon D. Ortiz, Leon D. Ortiz Colombia Section of Neuro-oncology, Instituto de Cancerologia, Clinica Las Americas, Medellin, Colombia,Search for more papers by this authorCamilo E. Fadul, Camilo E. Fadul Sections of Hematology/Oncology and Neurology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA, andSearch for more papers by this authorEva Horvath, Eva Horvath Department of Laboratory Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorKalman Kovacs, Kalman Kovacs Department of Laboratory Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author Luis V. Syro, Luis V. Syro Department of Neurosurgery, Hospital Pablo Tobon Uribe and Clinica Medellin, Medellin, Colombia,Search for more papers by this authorHumberto Uribe, Humberto Uribe Department of Neurosurgery, Clinica SOMA, Medellin, Colombia,Search for more papers by this authorLuis C. Penagos, Luis C. Penagos Division of Otolaryngology, Clinica Medellin, Medellin, Colombia,Search for more papers by this authorLeon D. Ortiz, Leon D. Ortiz Colombia Section of Neuro-oncology, Instituto de Cancerologia, Clinica Las Americas, Medellin, Colombia,Search for more papers by this authorCamilo E. Fadul, Camilo E. Fadul Sections of Hematology/Oncology and Neurology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA, andSearch for more papers by this authorEva Horvath, Eva Horvath Department of Laboratory Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorKalman Kovacs, Kalman Kovacs Department of Laboratory Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author First published: 05 September 2006 https://doi.org/10.1111/j.1365-2265.2006.02653.xCitations: 75Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Newlands, E.S., Stevens, M.F.G., Wedge, S.R., Wheelhouse, R.T. & Brock, C. (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Review, 23, 35–61. 2 Newlands, E.S., O'Reilly, S.M., Glaser, M.G., Bower, M., Evans, H., Brock, C., Brampton, M.H., Colquhoun, I., Lewis, P., Rice-Edwards, J.M., Illingworth, R.D. & Richards, P.G. (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. European Journal of Cancer, 32A, 2236–2241. 3 Yung, W.K., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M., Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S. & Levin, V.A. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Journal of Clinical Oncology, 17, 2762–2771. 4 Stupp, R., Gander, M., Leyvraz, S. & Newlands, E. (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncology, 2, 552–560. 5 Fadul, C.E., Kominsky, A.L., Meyer, L.P., Kingman, L.S., Kinlaw, W.B., Rhodes, C.H., Eskey, C.J., Pepin, S.E. & Simmons, N.E. (2004) Pituitary carcinomas respond to temozolomide. Neuro-Oncology, 6, 374. 6 Zhu, Y., Shahinian, H., Hakimian, B., Bonert, V., Lim, S. & Heaney, A. (2004) Temodar: novel treatment for pituitary carcinoma. US Endocrine Society, 43–5, 138. Citing Literature Volume65, Issue4October 2006Pages 552-553 ReferencesRelatedInformation
Referência(s)